Single‐Cell Transcriptome of Anaplastic Thyroid Cancer Reveals Immunosuppressive Tumor Microenvironment Remodeling
Cancer Medicine · 2026
DOI: 10.1002/cam4.72261 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, 2026. Verfasst von Saeko Tahara und 6 weiteren Autor:innen. Beteiligte Einrichtung: Bioinformatics Laboratory, Institute of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan. Hauptthemen laut MEDLINE: Tumor Microenvironment, Thyroid Carcinoma, Anaplastic, Thyroid Neoplasms, Transcriptome. Die Arbeit nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Japan Society for the Promotion of Science.
Abstract (Originalsprache)
Anaplastic thyroid cancer (ATC) is a rare but extremely aggressive malignancy responsible for most thyroid cancer–related deaths. To elucidate molecular and immunological characteristics distinguishing ATC from aggressive papillary thyroid cancer (PTC), we performed single‐cell RNA sequencing on three ATC and three lethal PTC samples. ATC tumor cells exhibited enhanced inflammatory and immune‐related gene expression, and co‐activation of MAPK and PI3K pathways. Notably, p53 pathway activity was suppressed in ATC, alongside activation of angiogenic and immune‐evasion programs, indicating a shift from proliferation‐driven to immune‐evasion–oriented signaling. Transcriptional network analysis revealed E2F family activation, including E2F1 , E2F7 , and E2F8 , suggesting CDK–RB–E2F axis dysregulation drives tumor dedifferentiation and proliferation, whereby p53 suppression unleashes E2F‐dependent transcriptional reprogramming. Immunoprofiling revealed CD8 + T cells in ATC showed elevated exhaustion signatures and high expression of inhibitory immune checkpoint molecules, accompanied by enhanced Treg–CD8 + T cell interactions, indicating a dual‐layered immunosuppressive mechanism involving both T‐cell exhaustion and enhanced Treg‐mediated suppression. In addition, we identified antigen‐presenting CAFs with altered CD4 + T‐cell interactions. These findings delineate a comprehensive single‐cell landscape of ATC and demonstrate coordinated alterations in tumor‐intrinsic signaling and the tumor microenvironment during dedifferentiation, provide a foundation for developing rational combination immunotherapies tailored to the molecular and immunological landscape of thyroid cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Bioinformatics Laboratory, Institute of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan.
- Department of Immunology, Institute of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan.
- Department of Breast and Endocrine Surgery, Institute of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan.
- Doctoral Program in Medical Science, Comprehensive Human Sciences, University of Tsukuba, Tsukuba, Ibaraki, Japan.
- Department of Breast-Thyroid-Endocrine Surgery, University of Tsukuba Hospital, Tsukuba, Ibaraki, Japan.
- R&D Center for Innovative Drug Discovery, University of Tsukuba, Tsukuba, Ibaraki, Japan.
ORCID-Profile: Saeko Tahara, Akiko Iguchi-Manaka, Tomohei Matsuo, Akira Shibuya, Kazuko Shibuya, Haruka Ozaki
Förderung
- Japan Society for the Promotion of Science
Zitieren
APA
Tahara, S., Iguchi-Manaka, A., Takeuchi, N., Matsuo, T., Shibuya, A., Shibuya, K., & Ozaki, H. (2026). Single‐Cell Transcriptome of Anaplastic Thyroid Cancer Reveals Immunosuppressive Tumor Microenvironment Remodeling. Cancer Medicine. https://doi.org/10.1002/cam4.72261
Vancouver
Tahara S, Iguchi-Manaka A, Takeuchi N, Matsuo T, Shibuya A, Shibuya K, et al. Single‐Cell Transcriptome of Anaplastic Thyroid Cancer Reveals Immunosuppressive Tumor Microenvironment Remodeling. Cancer Medicine. 2026. doi:10.1002/cam4.72261
BibTeX
@article{Tahara2026,
author = {Tahara, Saeko and Iguchi-Manaka, Akiko and Takeuchi, Naoto and Matsuo, Tomohei and Shibuya, Akira and Shibuya, Kazuko and Ozaki, Haruka},
title = {Single‐Cell Transcriptome of Anaplastic Thyroid Cancer Reveals Immunosuppressive Tumor Microenvironment Remodeling},
journal = {Cancer Medicine},
year = {2026},
doi = {10.1002/cam4.72261}
}
EUVIMED